Financial results
Biopharmaceutical company Merck and Company (NYSE: MRK) today released its Q1 2022 results report.
The company's shares opened on the plus side at $85.75 in today's trading. The stock has added +1.24% over the last 6 months.
The company's 52-week high is US$91.40 and the 52-week low is US$69.38.
As for the market capitalisation of Merck and Company, it currently stands at USD 221.41 billion.
Company report
Merck and Company said in its Q1 2022 report that worldwide sales from continuing operations in Q1 2022 were $15.9 billion. However, the company notes that this figure is 50% higher than in Q1 2021.
Also, the company's earnings per share under Generally Accepted Accounting Principles (GAAP) for Q1 2022 from continuing operations was $1.70.
The company stated that they were able to obtain multiple regulatory approvals and advanced clinical research pipeline.
As for the 2022 outlook, the company was able to increase and decrease global sales for 2022 from $56.9 billion to $58.1 billion, which means a projected annual growth rate of 17% to 19%.
Merck and Company was founded in 1891 in New York.
Executive team of the company:
Robert Davis;
Sanat Chattopadhyay;
Richard DeLuca;
Cristal Downing;
Arpa Garay;
Julie Gerberding;
Deepak Khanna;
Michael Klobuchar;
Dean Li;
Caroline Litchfield;
Steven Mizell;
Jannie Oosthuizen;
Dave Williams;
Jennifer Zachary.
You can read a detailed report from Merck and Company here.
Persons14 and Companies1 in the news
